FDA approves dostarlimab for advanced rectal cancer

• by Mouj Hijazi

• October 19, 2026

FDA grants Temab-A dual Breakthrough status

The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.

• by Mouj Hijazi

• October 7, 2026

• 3 min

AI diagnostics and what clinicians can verify in oncology

"The more AI changes what we do … the less able we are to check it.”

• by Lisa Astor

• October 1, 2026

• 8 min

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

• by Kathryn Wighton

• September 8, 2026

• 2 min